As part of a prestigious European Biotech Week event in Brussels today, PsiOxus Therapeutics has been revealed as the recipient of the EuropaBio Most Innovative European Biotech SME Award 2013. The award is now in its fourth year and has received applications from SMEs (small and medium sized enterprises) representing healthcare, industrial and agricultural biotechnologies
Upper Heyford , UK, 1 October 2013. The Native Antigen Company (NAC), specialists in the R&D and scale up manufacturing of highly pure viral and bacterial native antigens, today announced a world first. The release of all 4 Dengue Virus NS1 serotypes from human cell lines. All four DENV NS1 serotypes have been manufactured in
Henley-in-Arden, UK, 30 September 2013. Venture capital fund manager Mercia Fund Management (MFM) today announced a Seed Enterprise Investment (SEIS) in online marketing start-up Metric. Set to launch in January 2014, the company offers a suite of tools to create, manage and analyse e-marketing campaigns and promotions in real time. MFM has recently introduced a
Henley-in-Arden, 18 September 2013. Mercia Fund Management (MFM) has announced the appointment of Mike Hayes to spearhead the Venture Capital Fund’s new Digital and E-commerce Division. The new division will provide investment opportunities for high-growth potential businesses in the e-commerce, digital media and gaming sectors. Mike Hayes brings over 23 years’ experience in interactive businesses.
Mercia Fund Management leads investment in telecoms start-up Birmingham, UK 20 August 2013. Smart Antenna Technologies (SAT) today announced the launch of its innovative single-antenna technology for mobile devices. The technology will enable smartphone and tablet device manufacturers to replace several antennae with a single multi-band antenna, the performance of which will match that of
Cambridge UK, 30 July 2013 – Antitope Ltd (“Antitope”), a PolyTherics company, today announced a research agreement with ChemomAb Ltd of Tel Aviv, Israel (“ChemomAb”) for the generation of therapeutic antibodies for development as potential new treatments for inflammatory diseases. Under this agreement, Antitope will apply its Composite Human AntibodyTM technology to generate fully humanised
PolyTherics and Antitope combine to offer technologies for the development of better biopharmaceuticals Warwick, UK, 26 July 2013 – Mercia Fund Management (MFM) announces that one of its portfolio companies, PolyTherics Limited (“PolyTherics”), has merged with Antitope Limited (“Antitope”), the leading provider of antibody engineering and immunogenicity screening services, to create an enlarged group with
Henley-in-Arden, 22 July 2013 – Venture capital fund manager Mercia Fund Management (MFM) has announced £150,000 of funding in Oxford Genetics Ltd. The new biotechnology company is behind SnapFast™ – a system that simplifies the purchase of synthetic DNA molecules (plasmids). CEO of Oxford Genetics, Dr Ryan Cawood, invented the SnapFast™ system and likens it
Founded in a hot bed of fresh thinking and unique ideas, university spin-outs are becoming increasingly popular with both savvy investors, who can achieve a healthy return, and universities benefiting from funding channelled back into their R&D and facilities. Working with eight Midlands’ universities, Mercia Fund Management (MFM) has supported spin-outs from seed to successful
ColoAd1 study to compare direct intra-tumoral with intravenous injection in patients with non-metastatic colorectal cancer OXFORD, UK – June 18, 2013 – PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, will initiate a clinical trial of ColoAd1, a systemically available oncolytic vaccine, to compare the effectiveness of direct intra-tumoral injection with intravenous injection in